Literature DB >> 11292688

Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

A Weinrich Olsen1, L A van Pinxteren, L Meng Okkels, P Birk Rasmussen, P Andersen.   

Abstract

In this study, we investigated the potential of a tuberculosis subunit vaccine based on fusion proteins of the immunodominant antigens ESAT-6 and antigen 85B. When the fusion proteins were administered to mice in the adjuvant combination dimethyl dioctadecylammonium bromide-monophosphoryl lipid A, a strong dose-dependent immune response was induced to both single components as well as to the fusion proteins. The immune response induced was accompanied by high levels of protective immunity and reached the level of Mycobacterium bovis BCG-induced protection over a broad dose range. The vaccine induced efficient immunological memory, which remained stable 30 weeks postvaccination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292688      PMCID: PMC98224          DOI: 10.1128/IAI.69.5.2773-2778.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  ESAT-6 subunit vaccination against Mycobacterium tuberculosis.

Authors:  L Brandt; M Elhay; I Rosenkrands; E B Lindblad; P Andersen
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis.

Authors:  S L Baldwin; C D'Souza; A D Roberts; B P Kelly; A A Frank; M A Lui; J B Ulmer; K Huygen; D M McMurray; I M Orme
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

3.  Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis.

Authors:  L Brandt; T Oettinger; A Holm; A B Andersen; P Andersen
Journal:  J Immunol       Date:  1996-10-15       Impact factor: 5.422

4.  Duration of immunity to tuberculosis in mice vaccinated intravenously with oil-treated cell walls of Mycobacterium bovis strain BCG.

Authors:  R L Anacker; W R Barclay; W Brehmer; C L Larson; E Ribi
Journal:  J Immunol       Date:  1967-06       Impact factor: 5.422

5.  B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis.

Authors:  M Harboe; A S Malin; H S Dockrell; H G Wiker; G Ulvund; A Holm; M C Jørgensen; P Andersen
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

6.  DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.

Authors:  G Delogu; A Howard; F M Collins; S L Morris
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

7.  Vaccination against tuberculosis by DNA injection.

Authors:  R E Tascon; M J Colston; S Ragno; E Stavropoulos; D Gregory; D B Lowrie
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

8.  Proteins released from Mycobacterium tuberculosis during growth.

Authors:  P Andersen; D Askgaard; L Ljungqvist; J Bennedsen; I Heron
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

9.  Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines.

Authors:  I M Orme
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

10.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

View more
  103 in total

1.  Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice.

Authors:  Michela Sali; Gabriele Di Sante; Alessandro Cascioferro; Antonella Zumbo; Chiara Nicolò; Valentina Donà; Stefano Rocca; Annabella Procoli; Matteo Morandi; Francesco Ria; Giorgio Palù; Giovanni Fadda; Riccardo Manganelli; Giovanni Delogu
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

2.  Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model.

Authors:  Anja W Olsen; Ann Williams; Limei M Okkels; Graham Hatch; Peter Andersen
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

3.  Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system.

Authors:  Ida Rosenkrands; Else Marie Agger; Anja W Olsen; Karen S Korsholm; Claire Swetman Andersen; Klaus T Jensen; Peter Andersen
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  MHC-restricted Ag85B-specific CD8+ T cells are enhanced by recombinant BCG prime and DNA boost immunization in mice.

Authors:  Shihoko Komine-Aizawa; Jiansheng Jiang; Satoru Mizuno; Satoshi Hayakawa; Kazuhiro Matsuo; Lisa F Boyd; David H Margulies; Mitsuo Honda
Journal:  Eur J Immunol       Date:  2019-06-19       Impact factor: 5.532

5.  Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with hsp65 DNA.

Authors:  Jennifer L Taylor; Diane J Ordway; Jolynn Troudt; Mercedes Gonzalez-Juarrero; Randall J Basaraba; Ian M Orme
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination.

Authors:  Sang-Jun Ha; Su-Hyung Park; Hye-Ju Kim; Seung-Chul Kim; Hyang-Ju Kang; Eun-Gae Lee; Soon-Geon Kwon; Byong-Moon Kim; Sung-Hee Lee; Won-Bae Kim; Young-Chul Sung; Sang-Nae Cho
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

7.  Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine.

Authors:  Avi-Hai Hovav; Yolanta Fishman; Herve Bercovier
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

8.  Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection.

Authors:  Else Marie Agger; Joseph P Cassidy; Joseph Brady; Karen S Korsholm; Carina Vingsbo-Lundberg; Peter Andersen
Journal:  Immunology       Date:  2008-01-12       Impact factor: 7.397

9.  Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.

Authors:  Xindong Teng; Maopeng Tian; Jianrong Li; Songwei Tan; Xuefeng Yuan; Qi Yu; Yukai Jing; Zhiping Zhang; Tingting Yue; Lei Zhou; Xionglin Fan
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.

Authors:  Claire Swetman Andersen; Jes Dietrich; Else Marie Agger; Nils Y Lycke; Karin Lövgren; Peter Andersen
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.